Novavax Inc. logo

Novavax Inc. (NVAX)

Market Closed
21 Jul, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
8. 07
+0.19
+2.4746%
$
1.35B Market Cap
- P/E Ratio
- Div Yield
2.53M Volume
-4.28 Eps
$ 7.88
Previous Close
Add Transaction
Day Range
7.87 8.13
Year Range
6.2 11.97
Want to track NVAX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Novavax to Sell Czech Manufacturing Plant to Novo Nordisk for $200M

Novavax to Sell Czech Manufacturing Plant to Novo Nordisk for $200M

NVAX intends to use the payment from Novo to advance the development of its vaccine pipeline. The deal is expected to be closed by the end of this year.

Zacks | 1 year ago
2 Beaten-Down "Pandemic Stocks" to Consider for Contrarian Investors

2 Beaten-Down "Pandemic Stocks" to Consider for Contrarian Investors

Many companies that performed well in the early pandemic years have since fallen off the radar or at least have seen their shares drop substantially during the past three years. Telemedicine Teladoc Health (TDOC 0.64%) and vaccine maker Novavax (NVAX -1.31%) belong in this group: Both have significantly lagged behind the market since 2021.

Fool | 1 year ago
Novavax to sell Czech manufacturing unit to Novo Nordisk for $200 mln

Novavax to sell Czech manufacturing unit to Novo Nordisk for $200 mln

COVID-19 vaccine maker Novavax said on Wednesday it will sell its manufacturing facility in Czech Republic to Wegovy-maker Novo Nordisk for $200 million and use the proceeds for its vaccine pipeline.

Reuters | 1 year ago
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.

Zacks | 1 year ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX

NEW YORK, NY / ACCESSWIRE / November 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ:NVAX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Accesswire | 1 year ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX

NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ:NVAX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Accesswire | 1 year ago
Novavax Cut Its Outlook Despite Beating Third-Quarter Forecasts. Is It A Sell?

Novavax Cut Its Outlook Despite Beating Third-Quarter Forecasts. Is It A Sell?

Things were looking up for Novavax stock after the FDA resolved a clinical hold. But the company trimmed its outlook.

Investors | 1 year ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX

NEW YORK, NY / ACCESSWIRE / November 22, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ:NVAX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Accesswire | 1 year ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX

NEW YORK CITY, NY / ACCESSWIRE / November 20, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ:NVAX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Accesswire | 1 year ago
Novavax, Inc. (NVAX) Jefferies London Healthcare Conference (Transcript)

Novavax, Inc. (NVAX) Jefferies London Healthcare Conference (Transcript)

Novavax, Inc. (NASDAQ:NVAX ) Jefferies London Healthcare Results Conference November 20, 2024 6:00 AM ET Company Participants Jim Kelly - Executive Vice President, Chief Financial Officer and Treasurer Ruxandra Draghia - Head of R&D Conference Call Participants Roger Song - Jefferies Roger Song Alright. Okay. So, sorry for the couple minutes late, but it's my pleasure.

Seekingalpha | 1 year ago
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know

Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks | 1 year ago
NVAX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Novavax, Inc.

NVAX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Novavax, Inc.

NEW YORK, NY / ACCESSWIRE / November 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novavax, Inc. ("Novavax, Inc.") (NASDAQ:NVAX) concerning possible violations of federal securities laws. On October 16, 2024, NVAX announced the Food and Drug Administration placed a clinical hold on the development of the company's combination influenza and Covid-19 (CIC) shot and its stand-alone influenza vaccine.

Accesswire | 1 year ago
Loading...
Load More